NCT04521231 2026-04-16
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Phase 1/2 Recruiting
Clinical Trials
7 trialsNCT06308588 2026-04-14
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07134088 2026-03-30
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen
Phase 1/2 Recruiting
NCT07294677 2026-03-04
CAVALRY
University of Chicago
Phase 1/2 Recruiting
NCT06287229 2026-02-17
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05848687 2026-01-13
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Stanford University
Phase 1/2 Recruiting
NCT01371630 2025-12-18
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Recruiting